Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)
Source: View publication →
In patients with heart failure with preserved ejection fraction (HFpEF) and obesity, treatment with once-weekly semaglutide 2.4 mg led to substantially larger reductions in heart failure-related symptoms and physical limitations, greater weight loss, and improved exercise function compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
The STEP-HFpEF trial marks a fundamental paradigm shift in cardiovascular medicine by establishing obesity as a core, modifiable pathophysiologic driver of HFpEF rather than a mere bystander comorbidity. The +7.8 point difference in the KCCQ-CSS is among the largest improvements in patient-reported outcomes ever observed with any pharmacologic intervention in a heart failure trial. Consequently, it validates GLP-1 receptor agonists as highly effective, targeted therapies for the pervasive 'obesity-phenotype' of HFpEF, simultaneously addressing severe symptomatology, profound functional impairment, and systemic inflammation.
Historical Context
For decades, heart failure with preserved ejection fraction (HFpEF) was a notorious clinical challenge lacking targeted, highly effective therapies, resulting in purely symptom-based diuresis management. Over half of all HFpEF cases are complicated by an 'obesity phenotype'—distinguished by severe functional limitation, systemic inflammation, and excess visceral adiposity driving elevated filling pressures. Prior to 2021, no specific pharmacotherapy was FDA-approved for HFpEF until the advent of SGLT2 inhibitors (EMPEROR-Preserved, DELIVER). However, STEP-HFpEF was uniquely designed to directly target the underlying adiposity in this distinct phenotype, representing the first major breakthrough demonstrating that a primary anti-obesity agent (a GLP-1 receptor agonist) could robustly reverse heart failure symptomatology and dysfunction.
Guided Discussion
High-yield insights from every perspective
How does the pathophysiology of obesity-related heart failure with preserved ejection fraction (HFpEF) differ from other HFpEF phenotypes, and what are the proposed mechanisms by which a GLP-1 receptor agonist like semaglutide improves symptoms in these patients?
Key Response
Obesity-related HFpEF is driven by systemic microvascular inflammation, epicardial adipose tissue expansion, and mechanical restraint. Semaglutide induces weight loss, reducing mechanical load, but also has direct anti-inflammatory and endothelial benefits mediated through GLP-1 receptors.
Given that SGLT2 inhibitors are strongly recommended for HFpEF, how should the results of the STEP-HFpEF trial influence your decision to initiate semaglutide in an obese patient with HFpEF who is already on, or not yet on, an SGLT2 inhibitor?
Key Response
SGLT2 inhibitors remain the foundational disease-modifying therapy for HFpEF as they improve hard outcomes like hospitalizations. STEP-HFpEF showed semaglutide improves symptoms and weight regardless of background SGLT2 inhibitor use, suggesting it should be used as an additive therapy for symptom and weight management rather than a replacement.
The STEP-HFpEF trial utilized the KCCQ-CSS as a primary endpoint, but symptoms of obesity overlap heavily with HFpEF. How do we differentiate whether semaglutide is truly modifying the HFpEF disease process versus simply alleviating the dyspnea and fatigue inherent to severe obesity?
Key Response
The trial demonstrated reductions in NT-proBNP and CRP, along with improvements in the 6-minute walk distance. These biomarker and objective functional changes suggest true hemodynamic and inflammatory modification of the HFpEF phenotype rather than just unburdening the patient of excess adiposity.
With semaglutide emerging as a potent symptom-relieving therapy in obese HFpEF patients, how does this shift our overarching clinical paradigm from a purely hemodynamic approach to a cardiometabolic one, and what are the practical barriers to implementing this in routine practice?
Key Response
This shifts focus toward treating HFpEF as a systemic metabolic disorder where weight loss and metabolic optimization are central. Practical barriers include high drug costs, prior authorization hurdles, GI tolerability, and the need for multidisciplinary care to manage muscle mass loss during rapid weight reduction.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The STEP-HFpEF trial employed a dual primary endpoint including change in KCCQ-CSS. How does the predictable unblinding effect of profound weight loss with semaglutide threaten the validity of a subjective primary endpoint like the KCCQ, and what design approaches could mitigate this bias?
Key Response
Profound weight loss makes allocation concealment nearly impossible, potentially inflating patient-reported outcomes due to placebo or expectation bias. Researchers could mitigate this by heavily weighting objective co-primary endpoints like invasive hemodynamics, or by utilizing an active comparator that causes mild weight loss to preserve blinding.
While STEP-HFpEF demonstrated impressive improvements in KCCQ scores, it was not powered for hard clinical endpoints like cardiovascular mortality or heart failure hospitalizations. As an editor, how do you weigh the publication impact of symptomatic improvement against the absence of hard outcome data?
Key Response
Editors must balance clinical relevance with methodological scope. In HFpEF, where morbidity is high and few therapies exist, symptom improvement is highly valuable. However, editors must ensure authors do not overstate claims regarding mortality or disease-modifying outcomes without larger, longer-term endpoint trials.
Current ACC/AHA guidelines give SGLT2 inhibitors a Class 2a recommendation for HFpEF but lack specific recommendations for GLP-1 RAs in this population. Based on STEP-HFpEF, what level of evidence and class of recommendation should be assigned to semaglutide for obese HFpEF patients?
Key Response
STEP-HFpEF provides Level of Evidence A for symptom improvement and weight loss in the obesity-related HFpEF phenotype. The committee would likely grant a Class 2a recommendation for symptom management in patients with BMI > 30 and HFpEF, positioning it as an adjunctive cardiometabolic therapy to SGLT2 inhibitors.
Clinical Landscape
Noteworthy Related Trials
EMPEROR-Preserved
Tested
Empagliflozin 10 mg daily
Population
Patients with heart failure and ejection fraction >40%
Comparator
Placebo
Endpoint
Composite of cardiovascular death or hospitalization for heart failure
DELIVER
Tested
Dapagliflozin 10 mg daily
Population
Patients with heart failure and mildly reduced or preserved ejection fraction (>40%)
Comparator
Placebo
Endpoint
Composite of worsening heart failure or cardiovascular death
SELECT
Tested
Semaglutide 2.4 mg weekly
Population
Patients with preexisting cardiovascular disease and overweight or obesity but without diabetes
Comparator
Placebo
Endpoint
Composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (3-point MACE)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis